Skip To Main Content
Nicholas Kirk on Muck Rack

Nicholas Kirk

As seen in: Nature, Taylor & Francis Online, Science Magazine, Metacritic, BioRxiv, Cell Press, ADVFN-UK, FE Investegate, Newsrnd, TheBuyer

Get in touch with Nicholas

Contact Nicholas, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Articles

An engineered insulin analog with dual insulin and IGF-1 receptor agonism and distinct signaling

|
By Biswajit Moharana, Jingyu Sun, Qiwei Zhang, Irena Selicharová, Nicholas Kirk, Anna Kertisová, Marta Lubos, Katarina Mitrova, Lenka Žáková, Martina Chrudinová, Jana Brezinova, Karel Harant, Jan Voldřich, Miroslav Hájek, Derek M. Huffman
| Science Magazine Verified
Abstract INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS Acknowledgments Supplementary Materials REFERENCES Information & Authors Metrics & Citations View Options References Figures Tables Media Share Abstract Insulin and insulin-like growth factors (IGF-1 and IGF-2) regulate metabolism, growth, and development via related receptors. In contexts such as brain function or fetal development, coordinated signaling by all three hormones is essential.
Open in Who Shared Issue with article?

THIRD QUARTER 2025 TRADING UPDATE

|
By Nicholas Kirk
| sharesmagazine.co.uk
15 October 2025 THIRD QUARTER 2025 TRADING UPDATE EUROPE REMAINS CHALLENGING; GROWTH IN US AND ASIA Q3 Highlights* ·    Group gross profit of £187.8m, -6.7%* vs. 2024 ·    Resilient performance despite market uncertainty, variable results across the Group ·    Continued subdued levels of client and candidate confidence impacting decision making ·    Decrease in fee earner headcount of 120 (-2.3%) to 5,043 (Q2 2025: 5,163) ·    Gross profit per fee earner up 1% on Q3 2024 ·    Net cash of c.
Open in Who Shared View Duplicates (2) Issue with article?

THIRD QUARTER 2025 TRADING UPDATE

|
By Nicholas Kirk
| FE Investegate Verified
PageGroup plc reported a decrease in Group gross profit of 6.7% to £187.8m compared to 2024. Fee earner headcount decreased by 120 to 5,043, but gross profit per fee earner increased by 1%. The company's net cash position is approximately £38m, compared to £11m in Q2 2025 and £93m in Q3 2024. An interim dividend of £16.7m was paid. Europe experienced challenging conditions, while the US grew by 10%. The cost reduction program is on track to deliver annualised savings of £15m from 2026.
Open in Who Shared Issue with article?
See all 26 articles